FDA grants priority review for Bayer regorafenib NDA
The submission was based upon data from the pivotal, global Phase III CORRECT study. Regorafenib is an investigational oral multi-kinase inhibitor and is currently being investigated in clinical
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The partnership will use IDRI’s synthetic adjuvants in conjunction with Soligenix’s proprietary subunit proteins and thermostability platform (known as ThermoVax). Soligenix president and chief executive officer Christopher Schaber